Kiniksa Pharmaceuticals International Stock
Kiniksa Pharmaceuticals International, plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United Kingdom
- CEO
- Sanj K. Patel
- Employees
- 366
- Market cap
- $6.1 B
- IPO
- 24/05/2018
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company within the Healthcare sector, headquartered in London, United Kingdom. Founded in 2015, the company went public on the NASDAQ on May 24, 2018, and currently employs 366 employees. The business model focuses on the development and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Kiniksa Pharmaceuticals International stock: price history
1D
-1.7%
1W
-1.5%
1M
+1.2%
6M
+75.0%
YTD
+90.5%
1Y
+101.9%
2Y
+198.6%
5Y
+586.4%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~64% stronger price swings than usual
Kiniksa Pharmaceuticals International stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 15/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Kiniksa Pharmaceuticals International is a biopharmaceutical company that specializes in the development and commercialization of medical therapies. The core business is primarily based on the sales of the drug ARCALYST, which is used to treat recurrent pericarditis and cardiac sarcoidosis. In addition to this established product, the company is developing further active substances such as KPL-387 and KPL-116, which are in clinical trials or preclinical stages respectively. The business model is characterized by high research and development investments as well as the protection of intellectual property for the treatment of specific chronic diseases.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Kiniksa Pharmaceuticals International
Analyst assessment of Kiniksa Pharmaceuticals International
PRICE TARGET LOW
US$71.00
CONSENSUS
US$86.40
MEDIAN
US$90.00
PRICE TARGET HIGH
US$99.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 30/07/2026
Kiniksa Pharmaceuticals International stock metrics
P/E
73.45
P/B
9.32
EV/EBITDA
53.22
RETURN ON EQUITY
3.9%
NET MARGIN
10.4%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.6%
FLOAT SHARES
74,597,508
AVG. DAILY VOLUME (30D)
572,186
Insider transactions (SEC)
Moat Ross
Megna Michael R
Megna Michael R
Megna Michael R
Megna Michael R
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.7%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Kiniksa Pharmaceuticals International stock
What does Kiniksa Pharmaceuticals International do?
Kiniksa Pharmaceuticals International, plc is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United Kingdom.
The CEO is Sanj K. Patel, the company employs around 366 people.
The IPO was on 24/05/2018; the stock trades on NASDAQ under the ticker KNSA.
What do analysts say about Kiniksa Pharmaceuticals International stock?
11 analysts rate the stock, the consensus is Buy (as of 30/07/2026).
The average price target is US$86.40, ranging from US$71.00 to US$99.00, with a median of US$90.00.
This is an external assessment, not a statement by Market Jury.
When does Kiniksa Pharmaceuticals International report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 64% stronger than usual.
Does Kiniksa Pharmaceuticals International pay a dividend?
No, Kiniksa Pharmaceuticals International currently does not pay a dividend.
Which stocks are comparable to Kiniksa Pharmaceuticals International?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, GSK, Smith & Nephew, ConvaTec Group and LivaNova.
How can I get Kiniksa Pharmaceuticals International stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kiniksa Pharmaceuticals International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.